Cell & Gene Therapy Manufacturing: Scalability & Market Access Strategy
Description
Strategic analysis of CGT manufacturing bottlenecks limiting commercialization. Covers regulatory pathway maturation, HTA reimbursement uncertainty, and manufacturing scale-up economics. Market projections ($5.88B to $80B+) with capability assessment.
Table of Contents
72 Pages
- EXECUTIVE SUMMARY
- 1.1 CGT Market Overview & Growth Projections
- 1.2 Manufacturing Readiness Assessment
- 2.0 MANUFACTURING CHALLENGES
- 2.1 Autologous Therapy Manufacturing Economics
- 2.2 Allogeneic Approach & Scale-Up
- 2.3 Distributed Manufacturing Requirements
- 3.0 REGULATORY & REIMBURSEMENT
- 3.1 ATMP Regulatory Pathway Evolution
- 3.2 HTA & Pricing Strategy
- 3.3 Durability Data Requirements
- 4.0 VALUE CHAIN INTEGRATION
- 4.1 CDMO Partnership Strategy
- 4.2 Vertical Integration vs. Outsourcing
- 4.3 Time-to-Revenue Risk Management
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


